Outlook Therapeutics Reports Q1 Fiscal Year 2026 Financial Results

Published on February 19, 2026
ISELIN, N.J.—Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on improving the standard of care for bevacizumab in treating retina diseases, has announced its financial results for the first quarter of fiscal year 2026, which concluded on December 31, 2025. The company reported a net loss of $23.1 million for the quarter, which represents a decline compared with the $17.4 million net income reported in the same period of the prior year. The adjusted net loss for the quarter was $13.5 million, showing an improvement from the $21.6 million adjusted net loss recorded in the first fiscal quarter of 2025.
Continue reading on website
Other news

Women In Optometry Adds Seven New Advisory Board Members

February 19, 2026
NEW YORK—Women In Optometry (WO) announced it has welcomed seven new professional advisory board members to serve from 2026 to 2028. The WO professional advisory board plays a critical role in guiding editorial direction for the platform and alerting editors to important topics and issues, the announcement said. Each volunteer board member serves for a two-year period, with about half of the boar

LKC Technologies Announces Acquisition by AMETEK, Strengthening Its Long-Term Commitment to ECPs

February 19, 2026
GERMANTOWN, Md.—LKC Technologies, a leader in functional retinal testing using electroretinography (ERG), announced it has been acquired by AMETEK, Inc. (NYSE: AME), a global provider of industrial technology solutions. LKC Technologies said that the acquisition reflects the company’s continued growth, strong market adoption, and long-term commitment to supporting eyecare professionals worldwide.